The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2016 | Current treatments for cachexia
David Currow, BMed, MPH, FRACP, FAChPM, FAHMS of Flinders University, Adelaide, Australia discusses treatment for cachexia. He explains that to date, the only treatment option which has predictably changed the path of cachexia, is treating the underlying disease. None of the drugs under Phase III trials are currently available. In the future, there will be a need to systematically evaluate cachexia in clinical practice to ensure early signs are recognized. In the near future additional therapies are likely to become available. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
